Which has higher valuation & earnings, TELO or BBOT?

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A BridgeBio Oncology Therapeutics N/A N/A -$134.04M -$2.76 N/A

Is TELO or BBOT more profitable?

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% BridgeBio Oncology Therapeutics N/A -46.90% -42.17%

Which has preferable valuation and earnings, TELO or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is TELO or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -102.70% -90.75% Rocket Pharmaceuticals N/A -52.77% -44.92%

Is IPSC or TELO more profitable?

Century Therapeutics' return on equity of -49.51% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% Telomir Pharmaceuticals N/A -102.70% -90.75%

Is EVMN or TELO more profitable?

Evommune's return on equity of -62.63% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Telomir Pharmaceuticals N/A -102.70% -90.75%

Is ABEO or TELO more profitable?

Abeona Therapeutics' return on equity of -41.69% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -41.69% -30.36% Telomir Pharmaceuticals N/A -102.70% -90.75%

Telomir Pharmaceuticals (TELO) Competitors

$1.18 +0.01 (+0.85%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.26 +0.09 (+7.20%)

As of 10/2/2026 07:36 PM Eastern

Compare

TELO vs. BBOT, RCKT, IPSC, EVMN, and ABEO

Should you buy Telomir Pharmaceuticals stock or one of its competitors? Telomir Pharmaceuticals's main competitors and comparable companies include BridgeBio Oncology Therapeutics (BBOT), Rocket Pharmaceuticals (RCKT), Century Therapeutics (IPSC), Evommune (EVMN), and Abeona Therapeutics (ABEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Telomir Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Telomir Pharmaceuticals (NASDAQ:TELO) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Telomir Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 16.4% of Telomir Pharmaceuticals shares are held by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%

Telomir Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 238.98%. BridgeBio Oncology Therapeutics has a consensus target price of $22.88, indicating a potential upside of 488.05%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, BridgeBio Oncology Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for BridgeBio Oncology Therapeutics and 0 mentions for Telomir Pharmaceuticals. BridgeBio Oncology Therapeutics' average media sentiment score of 1.42 beat Telomir Pharmaceuticals' score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
BridgeBio Oncology Therapeutics	Positive

BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A

Summary

BridgeBio Oncology Therapeutics beats Telomir Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Rocket Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 0 mentions for Telomir Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.83 beat Telomir Pharmaceuticals' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Rocket Pharmaceuticals	Positive

Rocket Pharmaceuticals' return on equity of -52.77% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Telomir Pharmaceuticals has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Telomir Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 238.98%. Rocket Pharmaceuticals has a consensus target price of $8.63, indicating a potential upside of 236.91%. Given Telomir Pharmaceuticals' higher possible upside, equities analysts clearly believe Telomir Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rocket Pharmaceuticals beats Telomir Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Century Therapeutics' return on equity of -49.51% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

50.2% of Century Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Century Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	2.54	-$9.58M	-$0.93	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Century Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

Century Therapeutics currently has a consensus price target of $4.75, indicating a potential upside of 210.46%. Telomir Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 238.98%. Given Telomir Pharmaceuticals' higher possible upside, analysts clearly believe Telomir Pharmaceuticals is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Century Therapeutics had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Century Therapeutics and 0 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.00 beat Century Therapeutics' score of -0.12 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Century Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

Summary

Century Therapeutics beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Evommune?

Evommune (NYSE:EVMN) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Evommune had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Evommune and 0 mentions for Telomir Pharmaceuticals. Evommune's average media sentiment score of 0.45 beat Telomir Pharmaceuticals' score of 0.00 indicating that Evommune is being referred to more favorably in the media.

Company	Overall Sentiment
Evommune	Neutral
Telomir Pharmaceuticals	Neutral

Evommune's return on equity of -62.63% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Evommune. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	19.18	-$68.87M	-$11.03	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Evommune presently has a consensus target price of $33.33, indicating a potential upside of 385.13%. Telomir Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 238.98%. Given Evommune's stronger consensus rating and higher probable upside, equities analysts plainly believe Evommune is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Evommune beats Telomir Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does Telomir Pharmaceuticals compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Abeona Therapeutics had 15 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 15 mentions for Abeona Therapeutics and 0 mentions for Telomir Pharmaceuticals. Abeona Therapeutics' average media sentiment score of 0.31 beat Telomir Pharmaceuticals' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Abeona Therapeutics	Neutral
Telomir Pharmaceuticals	Neutral

Abeona Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 317.50%. Telomir Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 238.98%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Abeona Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Abeona Therapeutics' return on equity of -41.69% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-41.69%	-30.36%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

80.6% of Abeona Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abeona Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Abeona Therapeutics has higher revenue and earnings than Telomir Pharmaceuticals. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$25.52M	11.27	$71.18M	-$1.09	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Summary

Abeona Therapeutics beats Telomir Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Telomir Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELO vs. The Competition

Export

Metric	Telomir Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.16M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-1.30	12.93	273.77	26.04
Price / Sales	N/A	1,236.59	589.92	77.16
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	6.94	16.63	10.92	6.30
Net Income	-$10.41M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-4.07%	-3.10%	-2.07%	-1.67%
1 Month Performance	1.72%	-10.70%	-6.21%	-4.51%
1 Year Performance	-15.71%	19.46%	7.45%	2.03%

Telomir Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELO Telomir Pharmaceuticals	1.7151 of 5 stars	$1.18 +0.9%	$4.00 +239.0%	-15.1%	$81.16M	N/A	N/A	5
BBOT BridgeBio Oncology Therapeutics	4.1136 of 5 stars	$4.16 -10.7%	$22.88 +449.9%	N/A	$333.51M	N/A	N/A	88	Positive News Short Interest Decrease
RCKT Rocket Pharmaceuticals	2.5113 of 5 stars	$3.02 -9.9%	$8.63 +185.6%	-20.2%	$331.54M	N/A	N/A	202
IPSC Century Therapeutics	1.925 of 5 stars	$1.76 -6.9%	$4.75 +169.9%	+207.5%	$318.68M	$109.16M	N/A	78	News Coverage Analyst Forecast
EVMN Evommune	4.2616 of 5 stars	$8.75 -8.9%	$33.33 +281.1%	N/A	$317.39M	$13M	N/A	48

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELO) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. BBOT, RCKT, IPSC, EVMN, and ABEO

How does Telomir Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to Rocket Pharmaceuticals?

Summary

How does Telomir Pharmaceuticals compare to Century Therapeutics?

Summary

How does Telomir Pharmaceuticals compare to Evommune?

Summary

How does Telomir Pharmaceuticals compare to Abeona Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telomir Pharmaceuticals (TELO) Competitors

TELO vs. BBOT, RCKT, IPSC, EVMN, and ABEO

How does Telomir Pharmaceuticals compare to BridgeBio Oncology Therapeutics?

Which has more risk and volatility, TELO or BBOT?

Do institutionals and insiders believe in TELO or BBOT?

Is TELO or BBOT more profitable?

Do analysts rate TELO or BBOT?

Does the media refer more to TELO or BBOT?

Which has higher valuation & earnings, TELO or BBOT?

Summary

How does Telomir Pharmaceuticals compare to Rocket Pharmaceuticals?

Does the media refer more to TELO or RCKT?

Is TELO or RCKT more profitable?

Which has preferable valuation and earnings, TELO or RCKT?

Which has more volatility and risk, TELO or RCKT?

Do analysts recommend TELO or RCKT?

Do institutionals & insiders believe in TELO or RCKT?

Summary

How does Telomir Pharmaceuticals compare to Century Therapeutics?

Is IPSC or TELO more profitable?

Do insiders & institutionals believe in IPSC or TELO?

Which has better valuation and earnings, IPSC or TELO?

Which has more risk and volatility, IPSC or TELO?

Do analysts rate IPSC or TELO?

Does the media prefer IPSC or TELO?

Summary

How does Telomir Pharmaceuticals compare to Evommune?

Does the media prefer EVMN or TELO?

Is EVMN or TELO more profitable?

Which has preferable earnings and valuation, EVMN or TELO?

Do analysts recommend EVMN or TELO?

Summary

How does Telomir Pharmaceuticals compare to Abeona Therapeutics?

Does the media prefer ABEO or TELO?

Do analysts rate ABEO or TELO?

Is ABEO or TELO more profitable?

Do institutionals & insiders believe in ABEO or TELO?

Which has more risk & volatility, ABEO or TELO?

Which has stronger valuation & earnings, ABEO or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO vs. The Competition

Telomir Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools